Key result
Multimodality imaging and AI improve differential diagnosis and clinical management of sarcomeric HCM.
Why the study?
HCM follows variable progression patterns, and barriers persist regarding appropriate imaging timing and standardization of measures despite the benefits of multimodality imaging.
Multimodality imaging combined with AI offers significant potential for improving the diagnosis, management, and prognostication of patients with sarcomeric hypertrophic cardiomyopathy.
May aid sarcomeric HCM evaluation; leaves open need for prospective validation before practice change.
Hypertrophic cardiomyopathy (HCM) follows highly variable paradigms and disease-specific patterns of progression towards heart failure, arrhythmias and sudden cardiac death. Therefore, a generalized standard approach, shared with other cardiomyopathies, can be misleading in this setting. A multimodality imaging approach facilitates differential diagnosis of phenocopies and improves clinical and therapeutic management of the disease. However, only a profound knowledge of the progression patterns, including clinical features and imaging data, enables an appropriate use of all these resources in clinical practice. Combinations of various imaging tools and novel techniques of artificial intelligence have a potentially relevant role in diagnosis, clinical management and definition of prognosis. Nonetheless, several barriers persist such as unclear appropriate timing of imaging or universal standardization of measures and normal reference limits. This review provides an overview of the current knowledge on multimodality imaging and potentialities of novel tools, including artificial intelligence, in the management of patients with sarcomeric HCM, highlighting the importance of specific "red alerts" to understand the phenotype-genotype linkage.
No takes yet. Share an insight, caveat, or question.
Galluzzo et al. (2023) conducted a review in Sarcomeric Hypertrophic Cardiomyopathy. Multimodality imaging and artificial intelligence was evaluated. Multimodality imaging and artificial intelligence facilitate differential diagnosis and improve clinical management of sarcomeric hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: